Stockscreener 앱 받기
0.9125
4.87%
0.0424
전일 마감가:
$0.8701
열려 있는:
$1.13
하루 거래량:
63.47M
Relative Volume:
25.13
시가총액:
$109.76M
수익:
-
순이익/손실:
$-93.61M
주가수익비율:
-0.4325
EPS:
-2.11
순현금흐름:
$-71.16M
1주 성능:
+47.18%
1개월 성능:
+34.73%
6개월 성능:
+10.03%
1년 성능:
-4.62%
1일 변동 폭
$0.91
$1.20
1주일 범위
$0.59
$1.20
52주 변동 폭
$0.5062
$1.39
Immunic Inc Stock (IMUX) Company Profile
명칭
Immunic Inc
전화
(332) 255-9818
주소
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
0.9125 | 104.66M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-07 | 개시 | Roth Capital | Buy |
| 2025-09-29 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-25 | 개시 | William Blair | Outperform |
| 2024-11-25 | 개시 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-27 | 개시 | B. Riley Securities | Buy |
| 2022-10-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2021-04-15 | 개시 | Aegis Capital | Buy |
| 2021-03-24 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-02 | 개시 | SVB Leerink | Outperform |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-08-07 | 재개 | ROTH Capital | Buy |
| 2020-07-20 | 개시 | BMO Capital Markets | Outperform |
| 2020-06-05 | 개시 | Wedbush | Outperform |
| 2020-05-11 | 개시 | H.C. Wainwright | Buy |
| 2020-03-25 | 개시 | ROTH Capital | Buy |
| 2019-07-11 | 개시 | Chardan Capital Markets | Buy |
모두보기
Immunic Inc 주식(IMUX)의 최신 뉴스
Immunic MS trial shows reduced brain lesionsICYMI - Proactive financial news
Immunic (IMUX) Price Target Lowered by D. Boral Capital to $4.00 - GuruFocus
What’s the beta of Immunic Inc. stock2025 Bull vs Bear & Accurate Intraday Trading Signals - mfd.ru
A Look At Immunic (IMUX) Valuation After CEO Transition MS Data And US$200m Financing - simplywall.st
Immunic prices private placement of up to $400 million - The Pharma Letter
Immunic secures up to $400 million in private placement financing By Investing.com - Investing.com Nigeria
Market movers: Moderna, Pinterest, DraftKings, Coinbase, Immunic... - Proactive financial news
Why Is Immunic Stock Soaring Friday? - Bitget
Immunic stock soars after $400 million private placement deal - Investing.com
Why Is Immunic Stock (IMUX) Up 27% Today? - TipRanks
Immunic Stock Jumps After Pricing $400 Million Private Placement - Bitget
Immunic secured US$400 million to conclude phase 3 MS program and prepare for launch - European Biotechnology Magazine
Immunic Inc’s Stock Volatility: Market Reactions and Financial Insights - StocksToTrade
Immunic’s private placement; Vertex’s cystic fibrosis data in young kids - Endpoints News
Immunic (IMUX) Shares Surge 26% on $400M Funding and Leadership Changes - GuruFocus
Immunic to raise up to $400M to fund late-stage MS trials, commercial push - Proactive financial news
Why Did IMUX Stock Surge 33% Pre-Market Today? - Stocktwits
Immunic announces private placement, CEO change (IMUX:NASDAQ) - Seeking Alpha
D. Boral Capital Lowers Immunic (NASDAQ:IMUX) Price Target to $4.00 - MarketBeat
Immunic secures up to $400 million in private placement financing - Investing.com
Immunic Secures $200M Financing to Advance MS Programs - TipRanks
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company - The Malaysian Reserve
Immunic, Inc. Plans Transition of Daniel Vitt from CEO - marketscreener.com
Immunic announces oversubscribed private placement of up to USD 400 million to accelerate transformation into commercial-stage company - marketscreener.com
Immunic stock soars after $400 million private placement deal By Investing.com - Investing.com UK
Biopharmaceutical company Immunic, Inc. announced that its co-founder and current CEO, Daniel Vitt, will work with the board of directors to initiate the search for a new CEO. - Bitget
Immunic Signs Multiple Material Agreements - TradingView
The latest round of funding raised by Immunic, Inc. is expected to strongly support the company's strategic transformation—from a biotechnology enterprise focused on research and development to a fully integrated commercial entity with a complete industry c - Bitget
Immunic Announces Oversubscribed Private Placement Of Up To USD 400 Million To Accelerate Transformation Into Commercial-Stage Company - TradingView
EQS-News: Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Companyboerse.de - boerse.de
Immunic shares gain on $400M raise to fund late-stage MS trials, commercial push - Proactive financial news
Can Immunic Inc. stock rebound after recent weaknessJuly 2025 Big Picture & Real-Time Buy Zone Alerts - mfd.ru
Can Immunic Inc. ride the EV waveIPO Watch & Safe Capital Growth Plans - mfd.ru
Immunic showcases Phase 2 data on vidofludimus calcium at ACTRIMS Forum - Proactive financial news
HC Wainwright Reaffirms "Buy" Rating for Immunic (NASDAQ:IMUX) - MarketBeat
IMUX: HC Wainwright & Co. Reiterates Buy Rating with $8 Target | - GuruFocus
Is Immunic Inc attractive for institutional investorsInsider Buying & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Brookline Cap M Predicts Immunic FY2025 Earnings - MarketBeat
Immunic (NASDAQ:IMUX) Upgraded at Brookline Cap M - MarketBeat
Analysts Set Expectations for Immunic FY2025 Earnings - MarketBeat
Immunic (NASDAQ:IMUX) Upgraded at Brookline Capital Management - Defense World
Brookline Capital Management Upgrades Immunic (NASDAQ:IMUX) to "Strong-Buy" - MarketBeat
Immunic to present additional data on MS drug at ACTRIMS forum - Investing.com Nigeria
Small cap wrap: Fineqia, Immunic, M2i Global, Trust Stamp… - Proactive Investors
Immunic to present additional data on MS drug at ACTRIMS forum By Investing.com - Investing.com South Africa
Immunic to present additional Phase 2 data on vidofludimus calcium in progressive MS - Proactive financial news
MS trial: Immunic therapy cuts brain lesions and EBV signals - Stock Titan
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis - Sahm
Buyback Watch: Is Sandisk Corporation stock a top performer YTDPortfolio Gains Report & Target Return Focused Stock Picks - baoquankhu1.vn
Immunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Chipmakers Recap: Is Immunic Inc stock a good dividend stockJuly 2025 Reactions & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Immunic Inc (IMUX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Immunic Inc 주식 (IMUX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Tardio Jason | President and COO |
Jun 05 '25 |
Buy |
0.79 |
12,512 |
9,884 |
12,512 |
| Vitt Daniel | CEO and Director |
Jun 04 '25 |
Buy |
0.77 |
15,000 |
11,550 |
29,000 |
| Neermann Joerg | Director |
Jun 04 '25 |
Buy |
0.77 |
70,000 |
53,900 |
170,000 |
| Neermann Joerg | Director |
Jun 05 '25 |
Buy |
0.76 |
30,000 |
22,800 |
200,000 |
| Whaley Glenn | Chief Financial Officer |
Jun 03 '25 |
Buy |
0.71 |
45,000 |
32,076 |
95,510 |
| Rudick Richard Alan | Director |
Jun 03 '25 |
Buy |
0.70 |
143,075 |
100,024 |
230,375 |
1.12%
0.87%
자본화:
|
볼륨(24시간):